You know us for tech coverage, but you should follow us for biotech if you don’t already. In our latest no-paywall note we walk through the period between July and September, pelacarsen $NVS, ziltivekimab $NVO, eplontersen $AZN and milvexian $BMY all hitting their biological targets cleanly. Patients had no fewer heart attacks, strokes or deaths. Four for four.
Cestrian Capital Research, IncShare
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.